Abbvie M19-700- A Phase 1B Study Of Venetoclax In Combination With Pembrolizumab In Subjects With Previously Untreated Nsclc Whose Tumors Have High Pd-L1 Expression
Posted Date: Jul 8, 2020
- Investigator: John Morris
- Specialties: Cancer, Lung Cancer, Oncology
- Type of Study: Drug
The primary goal of this study is to determine the recommended dose of venetoclax in combination with pembrolizumab based on safety and anti-tumor activity (including tumor size kinetics).
Criteria:
To Be Eligible: Must Have Histologically Documented Advanced Or Metastatic Nsclc, Ecog 0 Or 1, At Least One Measurable Lesion, No Prior Treatment With Any Anti-Pd-1, Or Pd-L1 Or Pd-L2 Agent, No Known Cns Metastases, No Other Malignancy Within 3 Years, No Current Or Past Infection Or Comorbidity That May Impact Study Treatment/Safety,
Keywords:
Lung Cancer, Nsclc
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com